Rockefeller Capital Management L.P. Grows Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Rockefeller Capital Management L.P. raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 1.0% during the 3rd quarter, Holdings Channel reports. The firm owned 520,903 shares of the medical instruments supplier’s stock after purchasing an additional 5,051 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Becton, Dickinson and Company were worth $125,590,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its position in shares of Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after acquiring an additional 1,317,723 shares in the last quarter. PineStone Asset Management Inc. raised its holdings in Becton, Dickinson and Company by 141.6% in the 2nd quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after acquiring an additional 788,735 shares during the last quarter. First Eagle Investment Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 32.5% during the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after purchasing an additional 688,296 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Becton, Dickinson and Company by 9.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after purchasing an additional 460,440 shares during the period. Finally, Vaughan Nelson Investment Management L.P. purchased a new stake in Becton, Dickinson and Company in the 3rd quarter valued at about $108,243,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 1.0 %

Shares of BDX opened at $221.98 on Friday. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $249.89. The stock has a 50-day moving average price of $234.39 and a 200 day moving average price of $234.23. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The company has a market capitalization of $64.16 billion, a P/E ratio of 37.37, a P/E/G ratio of 1.65 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business’s revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the business posted $3.42 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.87%. The ex-dividend date is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is 63.97%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on BDX shares. Evercore ISI increased their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Raymond James reduced their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.